Last update 09 Jun 2025

TQB-3909

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
TQB-3909, TQB3909
Target
Bcl-2
Action
inhibitors
Mechanism
Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
Post-essential thrombocythemia myelofibrosisPost-polycythemia vera myelofibrosisPrimary Myelofibrosis+ [8]
Inactive Indication
Advanced breast cancerHormone receptor positive HER2 negative breast cancerMantle cell lymphoma recurrent+ [1]
Originator Organization
Nanjing Shunxin Pharmaceutical Co., Ltd.Nanjing Shunxin Pharmaceutical Co., Ltd.
Active Organization
Nanjing Shunxin Pharmaceutical Co., Ltd.Nanjing Shunxin Pharmaceutical Co., Ltd.Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

12
Clinical Trials associated with TQB-3909
NCT06245941
/ RecruitingPhase 1/2
A Phase Ib/II Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Moderate- and High-risk Myelofibrosis
CTR20240365
/ RecruitingPhase 1/2
评估TQB3909片联合阿扎胞苷在髓系恶性肿瘤受试者中安全性、有效性和药代动力学的Ib/II期临床试验
[Translation] A Phase Ib/II clinical trial evaluating the safety, efficacy, and pharmacokinetics of TQB3909 tablets combined with azacitidine in subjects with myeloid malignancies
NCT07011186
/ RecruitingPhase 1/2
A Phase Ib/II Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of TQB3909 Tablets in Combination With Azacitidine in Subjects With Myeloid Malignancies
100 Clinical Results associated with TQB-3909
Login to view more data
100 Translational Medicine associated with TQB-3909
Login to view more data
100 Patents (Medical) associated with TQB-3909
Login to view more data
100 Deals associated with TQB-3909
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Post-essential thrombocythemia myelofibrosisPhase 2
China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
13 May 2024
Post-polycythemia vera myelofibrosisPhase 2
China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
13 May 2024
Primary MyelofibrosisPhase 2
China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
13 May 2024
Acute Myeloid LeukemiaPhase 2
China
Nanjing Shunxin Pharmaceutical Co., Ltd.Nanjing Shunxin Pharmaceutical Co., Ltd.
25 Apr 2024
Myelodysplastic SyndromesPhase 2
China
Nanjing Shunxin Pharmaceutical Co., Ltd.Nanjing Shunxin Pharmaceutical Co., Ltd.
25 Apr 2024
Myeloid TumorPhase 2
China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
17 Apr 2024
Chronic lymphocytic leukaemia refractoryPhase 2
China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
11 Oct 2023
Small Lymphocytic LymphomaPhase 2
China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
11 Oct 2023
Mantle cell lymphoma recurrentPhase 2
China
Nanjing Shunxin Pharmaceutical Co., Ltd.Nanjing Shunxin Pharmaceutical Co., Ltd.
20 Sep 2023
Mantle cell lymphoma refractoryPhase 2
China
Nanjing Shunxin Pharmaceutical Co., Ltd.Nanjing Shunxin Pharmaceutical Co., Ltd.
20 Sep 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT04975204 (TQB3909-I-01, ESMO2024)
ManualManual
Phase 1
Acute Myeloid Leukemia | Non-Hodgkin Lymphoma
69
(CLL/SLL)
ekoikhhomz(wrddageaim) = None klyzfevnjh (fkegafvtnp )
View more
Positive
13 Sep 2024
(B-NHL)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free